Simeonov, Dimitre R. http://orcid.org/0000-0002-1693-8664
Brandt, Alexander J.
Chan, Alice Y.
Cortez, Jessica T.
Li, Zhongmei
Woo, Jonathan M.
Lee, Youjin
Carvalho, Claudia M. B.
Indart, Alyssa C.
Roth, Theodore L.
Zou, James http://orcid.org/0000-0001-8880-4764
May, Andrew P.
Lupski, James R.
Anderson, Mark S.
Buaas, F. William
Rokhsar, Daniel S.
Marson, Alexander
Funding for this research was provided by:
Foundation for the National Institutes of Health (DP3DK111914-01, R01HG0081410-01)
Article History
Received: 18 October 2018
Accepted: 15 January 2019
First Online: 18 February 2019
Competing interests
: A.M. is a co-founder of Spotlight Therapeutics, Arsenal Biosciences, and Sonoma Biotherapeutics. D.R.S. is a co-founder of Beeline Therapeutics. A.M. has served as an advisor to Juno Therapeutics and is a member of the scientific advisory board for PACT Pharma. The Marson lab has received sponsored research support from Juno Therapeutics, Epinomics and Sanofi and a gift from Gilead. The Marson lab has received funding from the Parker Institute for Cancer Immunotherapy (PICI) and the Innovative Genomics Institute (IGI). Baylor College of Medicine (BCM) and Miraca Holdings have formed a joint venture with shared ownership and governance of the Baylor Genetics (BG), which performs clinical microarray analysis and clinical exome sequencing. J.R.L. serves on the Scientific Advisory Board of the BG. J.R.L. has stock ownership in 23andMe, is a paid consultant for Regeneron Pharmaceuticals, and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. The remaining authors declare no competing interests.